# Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Bu

Source: https://onco.cc/trials/nct05822752/  
OnCo record `nct05822752` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Budigalimab, Livmoniplimab, Lenvatinib in hepatocellular carcinoma, run by AbbVie, active and no longer recruiting.

## Summary

Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) is a phase 2 interventional study registered as NCT05822752 by AbbVie, with 130 participants enrolled, started 2023-09-21 and due to reach its primary completion in 2026-11. Interventions recorded: Budigalimab, Livmoniplimab, Lenvatinib, Sorafenib. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05822752
- Phase: 2
- Setting: A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients Who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC
- Sponsor: AbbVie
- Enrolled: 130

## Sources

- ClinicalTrials.gov NCT05822752: https://clinicaltrials.gov/study/NCT05822752

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Budigalimab](https://onco.cc/drugs/budigalimab/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Livmoniplimab](https://onco.cc/drugs/livmoniplimab/), [Sorafenib](https://onco.cc/drugs/sorafenib/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct05822752.json